CMS Finalizes GLOBE Drug Payment Model

CMS Finalizes GLOBE Drug Payment Model

The model aims to deliver lower drug prices for those who have Original Medicare Part B while preserving quality of care.

The Centers for Medicare & Medicaid Services (CMS) is finalizing a mandatory drug payment model that will address the increasingly expensive cost of drugs under Original Medicare Part B.

U.S. citizens pay more than four times as much for brand-name prescription drugs as people in other developed countries, making affordability difficult or impossible for some. The Global Benchmark for Efficient Drug Pricing (GLOBE) Model will assess a rebate formula for certain drugs and biological products payable under Original Medicare Part B if the prices exceed those paid in economically comparable countries. Participation is mandatory for pharmaceutical manufacturers of Medicare Part B drugs that meet the GLOBE Model drug eligibility criteria and are not otherwise excluded.

Under the GLOBE Model, CMS will use manufacturer rebates when the price of the drug to Original Medicare exceeds that of an international benchmark based on what other comparable countries pay — making the net cost to Medicare for certain Part B drugs similar to what other comparable countries pay. Rebates paid by manufacturers will be sent directly to the Medicare Supplementary Medical Insurance Trust Fund, not patients. CMS anticipates that GLOBE will reduce out-of-pocket drug costs or coinsurance instead.

What’s Covered

The GLOBE Model focuses on drugs that are administered in a clinical healthcare setting, such as cancer therapies or drugs used to treat autoimmune conditions and arthritis. GLOBE excludes biosimilars and their reference biologicals once a biosimilar enters the market in the United States. The model also excludes orphan-only drugs, plasma-derived products, and certain cell and gene therapies, a change from the proposed rule made in response to public comments.

According to CMS: “Drugs included in the GLOBE Model are a subset of Part B rebatable drugs (single-source drugs and sole-source biological products) that are used to treat people with Medicare with conditions where there are potentially avoidable high program expenditures and access barriers due to high costs that likely contribute to deficits in care. GLOBE Model drugs will be selected from the oncology, rheumatology, immunology, ophthalmology, and endocrinology therapeutic classes (with certain exceptions) where annual Original Medicare spending exceeds $100 million.”

The Timeline

The GLOBE Model will operate for five years, beginning Jan. 1, 2027, and ending March 31, 2032, with pharmaceutical manufacturer rebate invoicing and reconciliation continuing until March 31, 2034. Reduced coinsurance amounts for GLOBE Model drugs are in effect from April 1, 2027, to March 31, 2032.

The model will apply to Medicare beneficiaries who reside in a randomly selected subset of geographic areas — approximately 25 percent of total Medicare beneficiaries who have Original Medicare as their primary coverage. Selected beneficiaries who will be impacted by the model may begin to see reduced out-of-pocket costs beginning April 1, 2027.

Visit CMS.com for a list of GLOBE Model frequently asked questions.


Resources:

CMS Finalizes New Mandatory Drug Payment Model to Deliver Lower Drug Prices for Beneficiaries in Original Medicare Part B

GLOBE (Global Benchmark for Efficient Drug Pricing) Model

GLOBE Model Frequently Asked Questions

Lee Fifield

medical coding books

About Has 331 Posts

Lee Fifield has a Bachelor of Science in communications from Ithaca College, Ithaca, New York, and has worked as a writer and editor for two decades.

Leave a Reply

Your email address will not be published. Required fields are marked *